NCT06645197View on ClinicalTrials.gov

An IIT Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of a Single Intrathecal Injection of SNUG01 in Patients with Amyotrophic Lateral Sclerosis

EARLY_PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

October 16, 2024

Primary Completion Date

April 15, 2025

Study Completion Date

October 15, 2029

Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
DRUG

SNUG01

Recombinant adeno-associated virus serotype 9 capsid containing human SG001 expression cassette

Trial Locations (5)

100000

Peking University Third Hospital, Beijing

210000

JiangSu Provincce Hospital, Nanjing

310000

Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou

350000

Fujian Medical University Union Hospital, Fujian

610000

West China Hospital of Sichuan University, Chengdu

All Listed Sponsors
collaborator

SineuGene Therapeutics Co., Ltd.

INDUSTRY

lead

Peking University Third Hospital

OTHER

NCT06645197 - An IIT Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of a Single Intrathecal Injection of SNUG01 in Patients with Amyotrophic Lateral Sclerosis | Biotech Hunter | Biotech Hunter